Receptor

Weight & Glucose Manager.

Truncated IGF-1 with localized hypertrophic action; favored for site-specific bodybuilding research.

Amylin analog co-developed with semaglutide as 'CagriSema' for next-gen weight loss.

Synonym/older spelling for Hexarelin; potent GH secretagogue with cardioprotective signaling.

Oral ghrelin-receptor agonist developed for cancer cachexia; approved in Japan as Adlumiz.

Oral non-peptide ghrelin-receptor agonist; FDA-approved as a veterinary appetite stimulant.

Daily GLP-1 analog; FDA-approved for diabetes (Victoza) and obesity (Saxenda®).

Weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment; sold as Trulicity by Eli Lilly.

Investigational GLP-1 / glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma.

First oral non-peptide GLP-1 receptor agonist (Eli Lilly); Phase 3 obesity program.

TGF-beta family ligand controversially linked to age-reversal via parabiosis studies.

Beta-endorphin C-terminal dipeptide investigated for opioid-tolerance modulation and CNS effects.

First-in-class GLP-1 mimetic derived from Gila monster venom; sold as Byetta/Bydureon.

Glycoprotein hormone with LH-mimetic activity that stimulates gonadal steroidogenesis; FDA-approved for cryptorchidism, select male hypogonadotropic hypogonadism, and ovulation induction.

Investigational small-molecule ERR (estrogen-related receptor) agonist studied preclinically as an exercise mimetic. Mouse data only; no human studies. Educational use only.

Investigational 11-amino-acid peptide derived from the helix-B region of erythropoietin that activates the innate repair receptor without stimulating red-blood-cell production; studied for small-fiber neuropathy.

Enclomiphene is the trans-isomer of clomiphene and a nonsteroidal selective estrogen receptor modulator (SERM). It has been investigated for secondary hypogonadism but has not received FDA approval; it may be available through compounding pharmacies in some jurisdictions.

Tamoxifen (Nolvadex) is a nonsteroidal SERM and the primary approved endocrine therapy for hormone receptor-positive breast cancer. Its use in males during or after testosterone therapy to manage gynecomastia or restore the hypothalamic-pituitary axis is off-label.